Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

141.14USD
11 Dec 2017
Change (% chg)

$0.55 (+0.39%)
Prev Close
$140.59
Open
$140.10
Day's High
$141.17
Day's Low
$139.83
Volume
4,358,269
Avg. Vol
5,179,952
52-wk High
$144.35
52-wk Low
$110.76

Latest Key Developments (Source: Significant Developments)

Zymeworks announces license agreement with Johnson & Johnson Innovation
Monday, 13 Nov 2017 05:00am EST 

Nov 13 (Reuters) - Zymeworks Inc :Zymeworks announces license agreement with Johnson & Johnson Innovation to develop and commercialize next generation bispecific antibody therapeutics.Says ‍US$50 million upfront license fee paid to Zymeworks for up to six bispecific programs​.Says Zymeworks licenses azymetric and efect platforms to Janssen​.Says ‍deal was facilitated by Johnson & Johnson Innovation​.Says co is eligible to potentially receive up to $282 million in development & up to US$1.12 billion in commercial milestone payments, tiered royalties.Says ‍Janssen also has option to develop two additional bispecific programs under agreement subject to a future option payment​.  Full Article

Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Protagonist Therapeutics Inc : :Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200.Protagonist Therapeutics - co is developing PTG-200 in collaboration with Janssen.  Full Article

J&J's Stelara shows positive results in treatment of systemic lupus erythematosus in phase 2 trial
Monday, 6 Nov 2017 08:00am EST 

Nov 6 (Reuters) - Johnson & Johnson ::Stelara® (ustekinumab) shows positive results in treatment of systemic lupus erythematosus in phase 2 trial.‍Janssen - positive results from randomized, placebo-controlled phase 2 study investigating anti-interleukin (il)-12/23 monoclonal antibody stelara​.‍P Janssen Research & Development says study met primary endpoint​.‍Janssen says plans to advance stelara into a phase 3 sle development program in 2018​.‍Janssen - stelara did not meet statistical significance in other secondary endpoints​.Janssen - ‍no deaths have been reported in study to date​.Janssen Research & Development says study met primary endpoint‍ (refiles to remove extraneous character)​.  Full Article

J&J says in Sept, co and Janssen were contacted by Texas and Colorado AG's offices
Thursday, 2 Nov 2017 04:33pm EDT 

Nov 2 (Reuters) - Johnson & Johnson :Johnson & Johnson - In September, co and Janssen Pharmaceuticals were contacted by the Texas and Colorado attorney general’s offices.Johnson & Johnson - co and Janssen Pharmaceuticals contacted on behalf of about 38 states regarding a multi-state attorney general investigation.Johnson & Johnson - The multi-state coalition served co and Janssen with subpoenas as part of the investigation related to opioids marketing practices.  Full Article

Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex
Tuesday, 31 Oct 2017 08:30am EDT 

Oct 31 (Reuters) - Halozyme Therapeutics Inc :Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​.Halozyme Therapeutics Inc - will receive a $15 million milestone payment from Janssen following dosing of third patient in a phase 3 trial​.  Full Article

Geron announces fast track designation grant for imetelstat
Tuesday, 31 Oct 2017 07:30am EDT 

Oct 31 (Reuters) - Geron Corp :Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes.Geron Corp - FDA grants fast track designation for potential treatment of adult patients with transfusion-dependent anemia​.Geron- J‍anssen sponsored application for fast track designation using preliminary data from clinical trial being conducted by Janssen in lower risk MDS​.  Full Article

Johnson & Johnson says FDA approved 10 mg dose of Xarelto for reducing continued risk for recurrent venous thromboembolism​
Monday, 30 Oct 2017 08:00am EDT 

Oct 30 (Reuters) - Johnson & Johnson -:FDA approves new 10 mg dosing for Xarelto® (rivaroxaban) to reduce the continued risk of venous thromboembolism (VTE).Janssen Pharmaceuticals says U.S. FDA approved 10 mg once-daily dose of Xarelto for reducing continued risk for recurrent venous thromboembolism​.  Full Article

Janssen Pharmaceutica says Phase 3 Amber study achieved its primary endpoint​
Wednesday, 25 Oct 2017 08:04am EDT 

Oct 25 (Reuters) - Johnson & Johnson :Investigational Darunavir-based single-tablet regimen shows positive results in previously untreated HIV patients in pivotal phase 3 Amber clinical trial.Janssen Pharmaceutica NV - Phase 3 Amber study achieved its primary endpoint​.  Full Article

Janssen receives two FDA approvals for SIMPONI ARIA for treatment of active psoriatic arthritis
Friday, 20 Oct 2017 04:23pm EDT 

Oct 20 (Reuters) - Johnson & Johnson :Janssen receives two U.S. FDA approvals for SIMPONI ARIA® (golimumab) for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis.‍Janssen Biotech says U.S. FDA approved SIMPONI ARIA for treatment of adults with active psoriatic arthritis or active ankylosing spondylitis​.  Full Article

Arcturus Therapeutics to collaborate with Johnson & Johnson
Thursday, 19 Oct 2017 07:00am EDT 

Oct 19 (Reuters) - Johnson & Johnson :Arcturus Therapeutics announces strategic collaboration with Johnson & Johnson Innovation to discover and develop RNA medicines.‍arcturus Therapeutics says has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals Inc​.‍arcturus Therapeutics Inc- agreement includes an option to expand into other infectious and respiratory diseases​.‍arcturus Therapeutics - deal was facilitated by Johnson & Johnson innovation center, in California​.‍arcturus Therapeutics - cos to work together to develop and commercialize nucleic acid-based drug products for treatment of Hepatitis B.Arcturus Therapeutics - ‍under agreement, Arcturus will receive an upfront cash payment, research and development support, pre-clinical, development, sales milestone payments​.  Full Article

Saddam Hussein at issue in 5th Circuit hearing in hip implant case

Johnson & Johnson argued before a federal appeals court on Thursday that a plaintiffs' lawyer improperly inflamed a jury that awarded $500 million in a hip implant case by suggesting the company had engaged in a range of unsavory conduct, including paying bribes to the regime of former Iraqi dictator Saddam Hussein.